Site-directed Chemical Modification of Recombinant Human aFGF Mutant with Polyethylene Glycol

A new product PEGylated rhaFGF was obtained by site-directed chemical modification.When compared with unmodified rhaFGF, PEGylated rhaFGF showed comparable bioactivity and superior stability at 37℃ in mouse serum and the stronger resistant potency to trypsin. This was accompanied by a substantial decreasing immunogenicity. Site-specific PEGylation of rhaFGF may increase its therapeutic potency in humans.